Back to Awarded Treatment Trials


Awarded Trial: 01T-411

Grant ID

01T-411

Illness

Schizophrenia

Primary Drug/Intervention

Galantamine

Primary Dosage

24 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Buchanan

Sample Size

80

Duration of Study Period for Each Subject

12 weeks

Outcome Measurements

Cognitive battery

Results

Eighty-six patients were enrolled and 73 completed the trial. Galantamine treatment did not differ from placebo on a composite score of cognitive measures but did show a benefit on verbal memory and the digit-symbol subtest.

Publication

Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008;165:82-89.

Link

http://www.ncbi.nlm.nih.gov/pubmed/17986678

PI Name

Robert Buchanan

Degree

MD

Center

Maryland Psychiatric Research Center

Institution

University of Maryland

Address

P.O. Box 21247

City or Town

Baltimore

State or Province

MD

Zip or Postal Code

21228

Country

USA

Email Address

rwbuchanan@mprc.umaryland.edu